TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06165536

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Resonant voice therapy
Description: Resonant voice therapy is a standard of care procedure for treating phonotraumatic vocal hyperfunction. The full standardized voice therapy program will have a duration of four weeks, each week with one 60-minute therapy session.
Study: NCT04803591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic Acid will be administered as an injectable solution (500mg/5ml or 1000mg/10ml).
Study: NCT05264103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton for gait rehabilitation (Atalante)
Description: Subjects will walk with different levels of assistance given by the robot.
Study: NCT05418686

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Capillary colchicine dosage in colchicine-resistant Familial Mediterranean Fever patients.
Description: * Adherence to colchicine therapy will be assessed by the Girerd questionnaire (6 questions ) completed by the patient at the inclusion visit.~* A blood sample (8ml) is taken, including a haemogram, CRP and creatinine and proteinuria.~* Standard on-site stool analysis for C. difficile toxin.~For research purposes, samples of:~* Stool. If the patient is unable to produce stools on the day of the visit, a collection kit with 2 tubes containing a preservative will be given to him/her as well as a stamped envelope to take the sample at home and send it by post within 10 days according to a validated procedure.~* A strand of hair with the diameter of a pencil and a minimum length of 2 cm, in the region of the posterior vertex.~* In patients with baldness or bleached hair only: pubic and/or axillary hair, a pencil-sized strand.~* Additional blood (5ml) and urine (2ml) samples for colchicine determination.
Study: NCT06127940

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Description: SBRT is delivered using institutional standard dosing while sotorasib is withheld during radiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temporary Stopping
Description: Temporary stop of sotorasib during SBRT
Study: NCT05750342

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental Product Caqui
Description: Supplement extracted from persimmon

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control product placebo
Description: Product with identical characteristics to the experimental product.
Study: NCT05494281

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus Anterior Plane Block with local anesthetic
Description: A deep analgesic block of the Serratus anterior plane block (SAPB) type by echo-guided lateral approach will be performed by An 8-13 Mhz high frequency linear ultrasound probe witch will be located cranio-caudally, transversely to the 3rd and 4th intercostal space on the mid-axillary line while patients are supine with the ipsilateral upper limb raised to 90°.~Once the landmark anatomical structures have been identified (upper rib, lower rib, pleural line, Serratus muscle, superficial structures), the puncture will begin Under aseptic conditions, an 80 mm 22 gauge needle will be inserted into the in-plane view of the ultrasound probe. When the needle has reached the plane under Serratus between the Serratus muscle and the intercostal muscle opposite the lower edge of the upper rib, 30 ml of 1% Lidocaine will be administered.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus Anterior Plane Block with saline solution
Description: A deep analgesic block of the Serratus anterior plane block (SAPB) type by echo-guided lateral approach will be performed by An 8-13 Mhz high frequency linear ultrasound probe witch will be located cranio-caudally, transversely to the 3rd and 4th intercostal space on the mid-axillary line while patients are supine with the ipsilateral upper limb raised to 90°.~Once the landmark anatomical structures have been identified (upper rib, lower rib, pleural line, Serratus muscle, superficial structures), the puncture will begin Under aseptic conditions, an 80 mm 22 gauge needle will be inserted into the in-plane view of the ultrasound probe. When the needle has reached the plane under Serratus between the Serratus muscle and the intercostal muscle opposite the lower edge of the upper rib, 30 ml of saline solution
Study: NCT05844865

Intervention type: OTHER
Group type: OTHER
Intervention: Biospecimen Collection (Blood, Ascites/Peritoneal Wash Fluid and/or Tumor Samples)
Description: Subjects with a known diagnosis of GI primary tumor with or without PC, with a planned standard of care surgery.
Study: NCT05304689

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: test for quantitative index of interleukins in the oral fluid
Description: collection of oral fluid and determination of the content of cytokines by test systems in patients with postoperative wound
Study: NCT05964751

Intervention type: DIAGNOSTIC_TEST
Intervention: lipid profile
Description: measuerments of lipid profile parameters to detect hyperlipidemia

Intervention type: DIAGNOSTIC_TEST
Intervention: lipid profile
Description: measuerments of lipid profile parameters to detect hyperlipidemia

Intervention type: DIAGNOSTIC_TEST
Intervention: lipid profile
Description: measuerments of lipid profile parameters to detect hyperlipidemia

Intervention type: DIAGNOSTIC_TEST
Intervention: fasting blood suger
Description: measurment of fasting blood suger to detect hyprerglicemia

Intervention type: DIAGNOSTIC_TEST
Intervention: fasting blood suger
Description: measurment of fasting blood suger to detect hyprerglicemia

Intervention type: DIAGNOSTIC_TEST
Intervention: fasting blood suger
Description: measurment of fasting blood suger to detect hyprerglicemia
Study: NCT05598606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab Injection
Description: 1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection plus intravenous placebo every 6 months (Q6M)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronate
Description: Intravenous zoledronic acid 5 mg plus subcutaneous placebo every 12 months
Study: NCT05172518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxane plus Intermittent Capecitabine
Description: Eligible patients will receive treatment with taxane (paclitaxel, nab-paclitaxel or docetaxel , the dosage reference to related prescribing information or clinical practice by investigators) plus capecitabine (1000 mg/ m2 twice daily D1-14 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy ), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone plus Intermittent Capecitabine
Description: Eligible patients will receive treatment with utidelone (30 mg/ m2 /day D1-5 Q3W) plus capecitabine (1000 mg/ m2 twice daily D1-14 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxane plus Metronomic Capecitabine
Description: Eligible patients will receive treatment with taxane (paclitaxel, nab-paclitaxel or docetaxel , the dosage reference to related prescribing information or clinical practice by investigators) plus capecitabine ( 500 mg three times daily on days 1-21 Q3W) for 6 \~8 cycles(For the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone plus Metronomic Capecitabine
Description: Eligible patients will receive treatment with utidelone (30 mg/ m2 /day D1-5 Q3W) plus capecitabine (500 mg three times daily on days 1-21 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy ), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
Study: NCT05172557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Program
Description: Wellness Program involves participation in classes with topics involving resiliency, stress, physical activity, and nutrition to be completed within a few months of study participation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Coaching
Description: Wellness coaching sessions throughout 12 months of study participation
Study: NCT06094335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality rehabilitation
Description: Children in this group received Virtual Reality Rehabilitation plus traditional physical therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy
Description: Flexibility exercises, strengthening exercises, endurance exercises, and postural stability exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy
Description: Flexibility exercises, strengthening exercises, endurance exercises, and postural stability exercises
Study: NCT05279534

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Combination of strains Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485, and Pediococcus acidilactici CECT7483, twice daily for 15 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Combination of maltodextrin (E1400, qs) in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0, twice daily for 15 days
Study: NCT04938765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: Effect of 40mg/kg Magnesium sulfate bolus dosed to ideal body weight on intraoperative neuromonitoring

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 20 ml of normal saline bolus will be administered to the control group over 10 mins.
Study: NCT04996537

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Micro-video digiral learning
Description: On the digital platform, you can accept courses anytime, anywhere, and repeat learning, answering, leaving messages, or interacting with lecturers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Micro-video digiral learning
Description: On the digital platform, you can accept courses anytime, anywhere, and repeat learning, answering, leaving messages, or interacting with lecturers.
Study: NCT06545110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baricitinib Oral Tablet
Description: Baricitinib 2/4mg giving to patients with sever alopecia areata after assessment Retinol Binding Protein 4 and its genetic variations.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Baricitinib Oral Tablet
Description: Baricitinib 2/4mg giving to patients with sever alopecia areata after assessment Retinol Binding Protein 4 and its genetic variations.
Study: NCT06171503

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: letter of invitation on MI in PMTCT service
Description: A non randomized control trial for the total of six month duration will be employed: the first phase is base line survey (pretest) to determine the magnitude of MI and qualitative method using FGD, IDI and KI with selected group to complement the base line will be conducted. Phase 2 Simultaneously with base line, the intervention will be employed to evaluate the effectiveness of invitation letter through mother support group to pregnant women attending antenatal clinic with out her partner as a strategy for male involvement in PMTCT/ANC services. End line data using qualitative approaches will be collected from partners attending antenatal care clinic following letter of invitation to evaluate the effectiveness of letter of invitation.
Study: NCT06281626

Intervention type: OTHER
Intervention: Data collection
Description: Data collection
Study: NCT06214598

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplement
Description: Supplements of anti-inflammatory oils rich in omega-3 and gamma-linolenic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AI diet
Description: diet rich in whole grains, healthy oils and polyphenols,

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo caps with standard diet
Study: NCT05692271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: 40 mg teva-propranolol taken twice daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT06497712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Before the beginning of stitches, the patient will be offered a hypnotic induction. The hypnotic induction is the initial phase of the hypnosis process. Its goal is to bring the patient to a state of dissociation: the hypnotic trance. Induction is usually achieved through progressive relaxation, sensory focusing, and a process of confusion.
Study: NCT05818436

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure: prosthetic functioning
Description: Prosthetic reline and occlusal stabilization through repair of missing pieces and recovery of occlusal contacts

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional dental prosthesis
Description: : conventional prosthetic treatment new prosthesis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional dental prosthesis
Description: : conventional prosthetic treatment new prosthesis
Study: NCT05033899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Description: to compare between Enhanced Recovery After Surgery (ERAS) protocol and conventional care in non-insulin dependent diabetic patients undergoing lumbar spine surgery.
Study: NCT05373225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acetic acid shockwave phonophoresis therapy
Description: This group composed of subjects. They will take 6 sessions with Time between sessions 5-7 days plus exercise and dietary advice

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shock wave Therapy
Description: This group composed of subjects and represented the control group who will receive shock wave therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy program
Description: Exercise program:~* Standing calf-stretching exercise~* Towel stretch: stretching exercise~* Ice bottle~* Towel pickup exercise~* Marble pickups exercise~* Calf raises exercises -Static and dynamic balance exercise
Study: NCT05280743

Intervention type: DRUG
Intervention: Oxycodone
Description: exposure to opioids after Cesarean Section

Intervention type: DRUG
Intervention: Oxycodone
Description: exposure to opioids after Cesarean Section
Study: NCT05493098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling
Description: The method of performing the dry needling technique will be based on the methods presented by Dommerholt and Fernandez-de-Las-Penas. One length of sterile, disposable 0.30 mm x 30 mm solid filament needle (Tony, China) will be used. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted to obtain local twitch response, and this process will continue until no more Dry needling:~The method of performing the dry needling technique will be based on the methods presented by Dommerholt and Fernandez-de-Las-Penas. One length of sterile, disposable 0.30 mm x 30 mm solid filament needle (Tony, China) will be used. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted to obtain local twitch response, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sham (placebo) dry needling:
Description: The sham dry needling method includes the insertion of the needles subcutaneously and no local twitch response will be obtained. The needles will be left in the place for 20 minutes.
Study: NCT05965960

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TUS Active
Description: Bilateral M1s/GPis will be sonicated using NeuroFUS device for two minutes per hemisphere with theta burst protocol and 30 W/cm2 Isppa

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TUS Sham
Description: Bilateral M1s/GPis will be sonicated using NeuroFUS device for two minutes per hemisphere with theta burst protocol and 0 W/cm2 Isppa
Study: NCT04922645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Citrate 1 gram Oral Tablet
Description: Ferric citrate is an iron-based phosphate binder for the treatment of hyperphosphatemia in subjects with dialysis-dependent chronic kidney disease (DD CKD) and for the treatment of iron deficiency anemia (IDA) in subjects with non-dialysis dependent chronic kidney disease (NDD CKD).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care phosphate-lowering therapy
Description: Subjects randomized to SOC will continue their currently prescribed dose of phosphate lowering therapy which will be dosed per local standard of care to achieve community target serum phosphate goals.
Study: NCT06478108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRSW-MIM
Description: IRSW-MIM collects patient's data and outputs a therapeutical strategy for treating advanced solid tumors.
Study: NCT06292559

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bilateral STN deep brain stimulation
Description: patients with Meige syndrome underwent bilateral subthalamic stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral GPi deep brain stimulation
Description: patients with Meige syndrome underwent bilateral pallidal stimulation
Study: NCT04662736

Intervention type: OTHER
Intervention: patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy
Description: description of osteo-articular infection managed with tedizolid as a suppressive antibiotic therapy
Study: NCT04584333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief intervention
Description: Group 1 (intervention group): depending on the willingness to change evaluated with the RCQ at each visit, the characteristics of the intervention to be performed will be established. Prochaska and DiClemente (1983) proposed a transtheoretical model of change in which different stages of change are identified that have been found to be predictive of adherence to treatment and its efficacy (Prochaska, Norcross and DiClemente, 1994). The RCQ includes three of the stages of change: Precontemplation, Contemplation and Action. In the Precontemplation stage, the person does not consider that he has a problem and has no intention of changing, in the Contemplation stage, he begins to contemplate that he has a problem and the possibility of change is raised and in the action stage, he has already started actively make a change in your behavior.
Study: NCT02446379

Intervention type: DRUG
Intervention: The marketed product 2-5 MBq/kg 18F-fluorodeoxyglucose
Description: The FDG is injected at least 120 minutes prior to the imaging by the EnLightTM and LightPathTM Imaging Systems

Intervention type: DEVICE
Intervention: EnLightTM
Description: The surgical cavity and the resected lymph nodes (if any) will be imaged by the EnLightTM system to establish whether radioactive tissue remains after surgery.

Intervention type: DEVICE
Intervention: LightPathTM Imaging System
Description: The resected tumour excision specimens and the resected lymph nodes (if any)will be imaged by CLI and by WLI to establish whether they contain radioactive tissue.
Study: NCT05912569

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delay sentinel node biopsy
Description: In the case of a patient undergoing breast-conserving surgery for intraductal carcinoma, the sentinel lymph node is not excised during the primary surgery but only marked for identification. I
Study: NCT05006417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: reconstituted at 100 units/mL, dosage will be based upon the affected muscles
Study: NCT06149143

Intervention type: DEVICE
Intervention: Cardiac Performance System (NSR)
Description: Participants will be asked to wear the Cardiac Performance System, a non-invasive sensor device on their upper abdomen. The Cardiac Performance System monitoring device will continuously monitor cardiac function.
Study: NCT04372537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hypnosis
Description: use of hypnosis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: standard clinical procedure
Study: NCT06370117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buzzy
Description: Before the procedure; 60 seconds before starting the vascular access process, the Buzzy® tool was placed in the procedure area and cold and vibration application was started. The tourniquet was tied 10-12 cm above the vein to be treated. The Buzzy® tool was fixed to the middle part of the procedure area and the tourniquet, approximately 2 cm above the IV catheter entry site.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music video listening
Description: Before the procedure; A music video was played 60 seconds before starting the intravenous access procedure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buzzy+ Music video listening
Description: 60 seconds before starting the vascular access process, a music video was played and cold and vibration application was started with the Buzzy® tool. 60 seconds before the procedure began, the Buzzy® tool was placed on the procedure area and cold and vibration application was initiated. The tourniquet was tied 10-12 cm above the vein to be treated. The Buzzy® tool was fixed midway between the procedure area and the tourniquet, approximately 2 cm above the IV catheter entry site.
Study: NCT04835233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methyldopa 250 MG
Description: maintaining postpartum the use of methyldopa 250 mg 01 tablet every 8 hours, being able to double the dose depending on pressure levels, up to 15 days postpartum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyldopa 250 MG
Description: maintaining postpartum the use of methyldopa 250 mg 01 tablet every 8 hours, being able to double the dose depending on pressure levels, up to 15 days postpartum